Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy

The results of a recently completed Phase III clinical trial suggest that concurrent chemoradiotherapy followed by tecemotide provides superior benefits to Stage IIIa and IIIb non-small cell lung carcinoma patients as compared with sequential chemoradiotherapy followed by tecemotide. These clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Kao, Chiao-Jung, Wurz, Gregory T, Schröder, Andreas, Wolf, Michael, DeGregorio, Michael W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896473/
https://www.ncbi.nlm.nih.gov/pubmed/24498545
http://dx.doi.org/10.4161/onci.26285
Descripción
Sumario:The results of a recently completed Phase III clinical trial suggest that concurrent chemoradiotherapy followed by tecemotide provides superior benefits to Stage IIIa and IIIb non-small cell lung carcinoma patients as compared with sequential chemoradiotherapy followed by tecemotide. These clinical observations will be dissected in a transgenic model of lung cancer that we have recently established (hMUC1.Tg C57BL/6 mice).

Ejemplares similares